Chile interested in expanding cooperation with St. Petersburg Research Institute

13 September 2017

GMP News

A meeting between the representatives of Instituto de Salud Pública, Chile, and St. Petersburg Research Institute of Vaccines and Serums was held in St. Petersburg.

The Chilean side represented by Pablo Ortiz Diaz, the Managing Finance Director, showed interest in expanding the cooperation with St. Petersburg Research Institute of Vaccines and Serums in assessing the potential for the presence of Russian immunobiological products in the market of Chile and other countries of the region. At the meeting, the parties agreed to sign a framework agreement on cooperation, which would include organizing the supplies of immunobiological products, joint research and development, as well as the creation of talent pool in the area of biotechnology.

“This meeting with Chilean colleagues is an important step in the development of relations both between our countries and across the Latin America. Chile pursues a consistent policy for prevention of viral diseases in population of the country, and the authorities are closely monitoring the implementation of the National Immunization Program and selection of required drugs,” said Stanislav Uiba, the Director General of MECHNIKOV Latin American Biotechnology Institute, after the meeting.

The competencies of Instituto de Salud Pública are especially important for the Russian side because of the project for construction of MECHNIKOV Latin American Biotechnology Institute implemented by St. Petersburg Research Institute of Vaccines and Serums in Nicaragua. Among other things, the activities of the Institute will be aimed at combating dangerous and rare viral diseases in Latin America and the Caribbean.


Previous publication Next publication

Media Center

  • 16 February 2018

    Pfizer taps BC for real-world cardiovascular research drive

    Pfizer has teamed up with BC Platforms to generate real-world evidence on cardiovascular diseases. The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.

  • 16 February 2018

    Pharma and AI: Help doctors with AI assistants but don’t try to replace them

    Dr. Robot gets a thumbs down from patients, according to new research from Syneos Health. Despite tech and investor enthusiasm, along with media headlines highlighting artificial intelligence in healthcare, patients are adamant that artificial intelligence should not replace doctors.

  • 15 February 2018

    Pharma Looks to Change the Healthcare Cost Conversation

    Amidst the continuing clamor for government action to curb prescription drug prices, a more collaborative effort aims to broaden the debate to consider the full range of healthcare services and rates that affect spending in this area. The National Pharmaceutical Council (NPC), a pharma-funded research organization, is partnering with the independent journal Health Affairs to examine the root causes of rising healthcare outlays in the United States. This two-year program will support academic and professional research projects and commentaries to be published and disseminated online by the journal.

  • 15 February 2018

    FDA Releases Guidance on Systemic Antibacterial Drugs

    FDA published guidance on the development, analysis, and presentation of microbiology data during the development of antibacterial drugs. The agency discusses the overall microbiology development program it says is needed to support clinical development and approval of antibacterial drugs administered systemically. The guidance also addresses microbiology data collected after drug approval.

Read more